

[网站首页](#)[本刊简介](#)[编委会](#)[投稿指南](#)[过刊浏览](#)[联系我们](#)[最新刊](#)位置: [首页](#) >> [期刊文章](#)

阿德福韦酯联合扶正化瘀胶囊治疗HBV DNA阴性代偿期肝硬化临床疗效观察

作者: [谌晓东](#) [彭永红](#) [卢流海](#)单位: [江西省万载县人民医院](#)关键词: [阿德福韦酯](#) [扶正化瘀胶囊](#) [HBV DNA阴性](#) [肝硬化](#)

分类号:

出版年,卷(期):页码: 2011,3(2):5-9

摘要:

摘要: 目的 观察阿德福韦酯(ADV)联合扶正化瘀胶囊治疗HBV DNA阴性代偿期肝硬化患者的疗效。方法 56例HBV DNA阴性代偿期肝硬化患者随机分为两组,对照组27例,给予常规保肝及抗纤维化治疗;治疗组29例,在对照组基础上加服ADV治疗。观察两组患者治疗前及治疗后12、24、36、48周时症状、体征、肝功能、血清肝纤维化指标及HBV DNA低于检测下限的比率。结果 治疗48周后,与治疗前相比,治疗组症状、体征、肝功能及血清肝纤维化的指标显著恢复($P < 0.05$);与对照组相比,治疗组患者肝纤维化的指标改善及HBV DNA低于检测下限的比率更为显著。治疗组并发症例数和病死率显著低于对照组。结论 ADV联合扶正化瘀胶囊治疗HBV DNA阴性代偿期肝硬化具有显著的疗效。

Abstract: Objective To observe the clinical effect of adefovir dipivoxil (ADV) combined with Fuzhenghuayu capsule on compensated liver cirrhosis patients with HBV DNA negative. Methods Total of 56 HBV DNA negative compensated liver cirrhosis patients were randomly divided into therapy group (27 cases) and control group (29 cases). The control group received conventional liver protector and anti-fibrosis treatment. The therapy group were treated with ADV add on treatment on the basis of control. The symptoms, signs, liver function, serum indexes of liver fibrosis and HBV DNA negative rate of two groups were observed before treatment and 12, 24, 36, 48 weeks after therapy. Results After treatment for 48 weeks, symptoms, signs, liver function, serum liver fibrosis indexes in treatment group markedly recovered ($P < 0.05$). Compared with the control group, the improvement of liver fibrosis index and HBV DNA negative rate of patients in therapy group were more obvious. The complications and mortality in therapy group were obviously lower than that of control group. Conclusions ADV and Fuzhenghuayu capsule are beneficial for compensated liver cirrhosis patients with HBV DNA negative.

基金项目:

作者简介:

参考文献:

服务与反馈:

[【文章下载】](#) [【加入收藏】](#)